CLSD Clearside Biomedical Inc

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: . The live call can be accessed by dialing (877) 545-0523 (domestic) or (973) 528-0016 (international) and entering conference code: 756568. The Company suggests participants join 15 minutes in advance of the event.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, , for the treatment of neovascular age-related macular degeneration (wet AMD), recently completed a Phase 2b clinical trial, and planning for a Phase 3 program is underway. Clearside developed and gained approval for its first product, for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit or follow us on and .

Investor and Media Contacts:

Jenny Kobin

Remy Bernarda



(678) 430-8206

Source: Clearside Biomedical, Inc.



EN
31/10/2024

Underlying

CLSDClearside Biomedical Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clearside Biomedical Inc

Free Trial
CLSD Clearside Biome...

Clearside Biomedical Inc: 1 director

A director at Clearside Biomedical Inc bought 36,500 shares at 1.000USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

CLSD CLEARSIDE BIOMEDICAL INC
7h / 13m 7h / 13m 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of...

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside’s Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezka...

November 4, 2024 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical to Report Third Quarter 2024 Financial Results an...

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss t...

October 31, 2024 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroida...

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Versatility of SCS Microinjector® Featured in Multiple Presentations - ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutica...

October 22, 2024 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Positive Topline Results from ODYSSEY P...

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, ...

October 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch